In this regard, Brown et al [7] recently provided a rationale for developing an immunotherapeutic approach for eradicating the GBM stem cell population by reporting that human tumor stem/initiating cells from GBM patients could be recognized and killed by CD8+ cytotoxic T lymphocytes. This evidence concerns the gene CD8A and glioblastoma.